Format
Sort by
Items per page

Send to

Choose Destination

Links from MedGen

Items: 1 to 20 of 975

1.

Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells.

Wang Y, Huang G, Zeng H, Yang K, Lamb RF, Chi H.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4894-903. doi: 10.1073/pnas.1308905110. Epub 2013 Nov 26.

2.

Deletion of tuberous sclerosis 1 in somatic cells of the murine reproductive tract causes female infertility.

Tanaka Y, Park JH, Tanwar PS, Kaneko-Tarui T, Mittal S, Lee HJ, Teixeira JM.

Endocrinology. 2012 Jan;153(1):404-16. doi: 10.1210/en.2011-1191. Epub 2011 Nov 29.

3.

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.

Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, DeClue JE.

Oncogene. 2000 Dec 14;19(54):6306-16.

4.
6.

COL5A1: fine genetic mapping and exclusion as candidate gene in families with nail-patella syndrome, tuberous sclerosis 1, hereditary hemorrhagic telangiectasia, and Ehlers-Danlos Syndrome type II.

Greenspan DS, Northrup H, Au KS, McAllister KA, Francomano CA, Wenstrup RJ, Marchuk DA, Kwiatkowski DJ.

Genomics. 1995 Feb 10;25(3):737-9.

PMID:
7759113
7.

Tsc1-dependent transcriptional programming of dendritic cell homeostasis and function.

Luo Y, Liu J, Sun X, Feng T, Fang L, Chen S, Fang C, Feng X, Huang H.

Exp Cell Res. 2017 Dec 30. pii: S0014-4827(17)30690-0. doi: 10.1016/j.yexcr.2017.12.028. [Epub ahead of print]

PMID:
29294307
8.

Correlation between TSC1 gene polymorphism and epilepsy.

Jiang X, Chen J, Song Q, Wang W, Zhang G, Li Y.

Exp Ther Med. 2017 Dec;14(6):6238-6242. doi: 10.3892/etm.2017.5345. Epub 2017 Oct 19.

9.

TSC1 Mutations in Keratoconus Patients With or Without Tuberous Sclerosis.

Bykhovskaya Y, Fardaei M, Khaled ML, Nejabat M, Salouti R, Dastsooz H, Liu Y, Inaloo S, Rabinowitz YS.

Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6462-6469. doi: 10.1167/iovs.17-22819.

10.

Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations.

Bongaarts A, Giannikou K, Reinten RJ, Anink JJ, Mills JD, Jansen FE, Spliet GMW, den Dunnen WFA, Coras R, Blümcke I, Paulus W, Scholl T, Feucht M, Kotulska K, Jozwiak S, Buccoliero AM, Caporalini C, Giordano F, Genitori L, Söylemezoğlu F, Pimentel J, Nellist M, Schouten-van Meeteren AYN, Nag A, Mühlebner A, Kwiatkowski DJ, Aronica E.

Oncotarget. 2017 Sep 8;8(56):95516-95529. doi: 10.18632/oncotarget.20764. eCollection 2017 Nov 10.

11.

TSC1 enables plastid development under dark conditions, contributing to rice adaptation to transplantation shock.

Shi X, Chen S, Peng Y, Wang Y, Chen J, Hu Z, Wang B, Li A, Chao D, Li Y, Teng S.

J Integr Plant Biol. 2017 Dec 6. doi: 10.1111/jipb.12621. [Epub ahead of print]

PMID:
29210524
12.

Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece.

Avgeris S, Fostira F, Vagena A, Ninios Y, Delimitsou A, Vodicka R, Vrtel R, Youroukos S, Stravopodis DJ, Vlassi M, Astrinidis A, Yannoukakos D, Voutsinas GE.

Sci Rep. 2017 Dec 1;7(1):16697. doi: 10.1038/s41598-017-16988-w.

13.

Analysis of TSC1 mutation spectrum in mucosal melanoma.

Ma M, Dai J, Xu T, Yu S, Yu H, Tang H, Yan J, Wu X, Yu J, Chi Z, Si L, Cui C, Sheng X, Kong Y, Guo J.

J Cancer Res Clin Oncol. 2017 Nov 28. doi: 10.1007/s00432-017-2550-z. [Epub ahead of print]

PMID:
29185092
14.

Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

Woodford MR, Sager RA, Marris E, Dunn DM, Blanden AR, Murphy RL, Rensing N, Shapiro O, Panaretou B, Prodromou C, Loh SN, Gutmann DH, Bourboulia D, Bratslavsky G, Wong M, Mollapour M.

EMBO J. 2017 Dec 15;36(24):3650-3665. doi: 10.15252/embj.201796700. Epub 2017 Nov 10.

15.

Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis.

Rosset C, Vairo F, Bandeira IC, Correia RL, de Goes FV, da Silva RTB, Bueno LSM, de Miranda Gomes MCS, Galvão HCR, Neri JICF, Achatz MI, Netto CBO, Ashton-Prolla P.

PLoS One. 2017 Oct 2;12(10):e0185713. doi: 10.1371/journal.pone.0185713. eCollection 2017.

16.

TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.

Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y, Zhang Y, Han L.

Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.349. [Epub ahead of print]

PMID:
28967907
17.

Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature.

Mortaji P, Morris KT, Samedi V, Eberhardt S, Ryan S.

Fam Cancer. 2017 Sep 8. doi: 10.1007/s10689-017-0029-3. [Epub ahead of print] Review.

PMID:
28887784
18.

Assessment of Response of Kidney Tumors to Rapamycin and Atorvastatin in Tsc1+/- Mice.

Shen MH, Samsel P, Shen LL, Narov K, Yang J, Sampson JR.

Transl Oncol. 2017 Oct;10(5):793-799. doi: 10.1016/j.tranon.2017.07.009. Epub 2017 Aug 24.

19.

miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma.

Wang Y, Zhang X, Tang W, Lin Z, Xu L, Dong R, Li Y, Li J, Zhang Z, Li X, Zhao L, Wei JJ, Shao C, Kong B, Liu Z.

Cell Death Differ. 2017 Dec;24(12):2089-2100. doi: 10.1038/cdd.2017.129. Epub 2017 Aug 11.

PMID:
28800130
20.

A brain proteomic investigation of rapamycin effects in the Tsc1+/- mouse model.

Wesseling H, Elgersma Y, Bahn S.

Mol Autism. 2017 Aug 1;8:41. doi: 10.1186/s13229-017-0151-y. eCollection 2017.

Supplemental Content

Support Center